| Mark Siegel, MD | |
|
789 Howard Ave, Fitkin Building, 2nd Floor, New Haven, CT 06519-1304 | |
| (203) 785-4198 | |
| (203) 737-5453 |
| Full Name | Mark Siegel |
|---|---|
| Gender | Male |
| Speciality | Pulmonary Disease |
| Experience | 26 Years |
| Location | 789 Howard Ave, New Haven, Connecticut |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1700861598 | NPI | - | NPPES |
| 001330810 | Medicaid | CT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0200X | Internal Medicine - Critical Care Medicine | 033081 (Connecticut) | Secondary |
| 207RP1001X | Internal Medicine - Pulmonary Disease | 033081 (Connecticut) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Yale-new Haven Hospital | New haven, CT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Yale University | 9436061736 | 2241 |
News Archive
Bayer HealthCare today announced that the company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for radium Ra 223 dichloride (radium-223), an investigational compound for the treatment of castration-resistant prostate cancer (CRPC) patients with bone metastases.
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published today in the European Journal of Preventive Cardiology.
Research in the field of kidney cancer, also called renal cancer, is vital, because many patients with this disease still cannot be cured today.
Researchers at the Department of Energy's Lawrence Berkeley National Laboratory and UC Berkeley have created a sort of nanoscale display case that enables new atomic-scale views of hard-to-study chemical and biological samples.
› Verified 6 days ago
| Entity Name | Yale University |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205822236 PECOS PAC ID: 9436061736 Enrollment ID: O20031105000015 |
News Archive
Bayer HealthCare today announced that the company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for radium Ra 223 dichloride (radium-223), an investigational compound for the treatment of castration-resistant prostate cancer (CRPC) patients with bone metastases.
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published today in the European Journal of Preventive Cardiology.
Research in the field of kidney cancer, also called renal cancer, is vital, because many patients with this disease still cannot be cured today.
Researchers at the Department of Energy's Lawrence Berkeley National Laboratory and UC Berkeley have created a sort of nanoscale display case that enables new atomic-scale views of hard-to-study chemical and biological samples.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mark Siegel, MD 789 Howard Ave, Fitkin Building, 2nd Floor, New Haven, CT 06519-1304 Ph: (203) 785-4198 | Mark Siegel, MD 789 Howard Ave, Fitkin Building, 2nd Floor, New Haven, CT 06519-1304 Ph: (203) 785-4198 |
News Archive
Bayer HealthCare today announced that the company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for radium Ra 223 dichloride (radium-223), an investigational compound for the treatment of castration-resistant prostate cancer (CRPC) patients with bone metastases.
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published today in the European Journal of Preventive Cardiology.
Research in the field of kidney cancer, also called renal cancer, is vital, because many patients with this disease still cannot be cured today.
Researchers at the Department of Energy's Lawrence Berkeley National Laboratory and UC Berkeley have created a sort of nanoscale display case that enables new atomic-scale views of hard-to-study chemical and biological samples.
› Verified 6 days ago
Dr. Brian Christopher Cambi, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 333 Cedar St, Dcb 3, New Haven, CT 06510 Phone: 203-785-4129 Fax: 203-737-2437 | |
Ms. Maryam Gondal, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 330 Cedar Street, Bb 114, New Haven, CT 06510 Phone: 203-785-4184 | |
Matthew Joseph Mcconnell, M.D. Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 333 Cedar St, Ynhh Internal Medicine-gi,section Of Digestive Diseases, New Haven, CT 06510 Phone: 203-785-7012 | |
Marie Anjeliese Rodriguez, Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 20 York St, New Haven, CT 06510 Phone: 203-688-4242 | |
Dr. Margaret M Xu, MD Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 20 York St, New Haven, CT 06510 Phone: 203-688-4242 | |
Carola Marte, MD Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 1450 Chapel St, Haelen Center, New Haven, CT 06511 Phone: 203-789-4135 Fax: 203-867-5241 | |
Jeanette M Tetrault, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1 Long Wharf Dr, New Haven, CT 06511 Phone: 203-781-4600 Fax: 203-781-4624 |